Literature DB >> 11257582

The cellular delivery of antisense oligonucleotides and ribozymes.

M D. Hughes1, M Hussain, Q Nawaz, P Sayyed, S Akhtar.   

Abstract

The design and development of antisense oligonucleotides and ribozymes for the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. Improvements in oligonucleotide chemistry have led to the synthesis of nucleic acids that are relatively stable in the biological milieu. However, advances in cellular targeting and intracellular delivery will probably lead to more widespread clinical applications. This review looks at recent advances in the in vitro and in vivo delivery of antisense oligodeoxynucleotides and ribozymes.

Entities:  

Year:  2001        PMID: 11257582     DOI: 10.1016/s1359-6446(00)00326-3

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  21 in total

1.  Ribozyme-Spherical Nucleic Acids.

Authors:  Jessica L Rouge; Timothy L Sita; Liangliang Hao; Fotini M Kouri; William E Briley; Alexander H Stegh; Chad A Mirkin
Journal:  J Am Chem Soc       Date:  2015-08-14       Impact factor: 15.419

2.  Quantitative detection of siRNA and single-stranded oligonucleotides: relationship between uptake and biological activity of siRNA.

Authors:  Marita Overhoff; Winfried Wünsche; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2004-12-02       Impact factor: 16.971

Review 3.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 4.  Efficient siRNA delivery with non-viral polymeric vehicles.

Authors:  Won Jong Kim; Sung Wan Kim
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

5.  Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2013-09-17

6.  Inorganic nanovectors for nucleic acid delivery.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Anisha A D'Souza; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

7.  Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells.

Authors:  San-Jun Shi; Zhi-Rong Zhong; Jie Liu; Zhi-Rong Zhang; Xun Sun; Tao Gong
Journal:  Pharm Res       Date:  2011-07-06       Impact factor: 4.200

8.  Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor.

Authors:  Andrew J Hollins; Mustapha Benboubetra; Yadollah Omidi; Bernd H Zinselmeyer; Andreas G Schatzlein; Ijeoma F Uchegbu; Saghir Akhtar
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

Review 9.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 10.  Nano-ART and NeuroAIDS.

Authors:  Malay K Das; Anupam Sarma; Tapash Chakraborty
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.